Počet záznamov: 1

ipilimumab

SYS		d000074324
LBL		00000nz--a2200181n--4500
005		20250606222449.3
008		180101\|\|\|anznnbabn-----------\|-a\|a------
040		$b slo $a BA006 $d BA006
065		$a D12.776.124.486.485.114.224.060.798
065		$a D12.776.124.790.651.114.224.060.798
065		$a D12.776.377.715.548.114.224.200.798
066		$a 01 $c 03
150		$a ipilimumab $x AD $x AE $x AN $x BI $x BL $x CF $x CH $x CL $x DE $x EC $x GE $x HI $x IM $x IP $x ME $x PD $x PH $x PK $x PO $x RE $x TO $x TU $x UL $x UR $2 slo
450		$w v $a anti-CTLA-4 MAb ipilimumab $2 slo
450		$w v $a MDX 010 $2 slo
450		$w v $a MDX-CTLA-4 $2 slo
550		$7 sllk_us_auth*d060908 $Y CTLA-4 Antigen $w b $a antigén CTLA-4
550		$7 sllk_us_auth*d000074322 $Y Antineoplastic Agents, Immunological $w P $a antineoplastiká imunologické
550		$7 sllk_us_auth*d000082082 $Y Immune Checkpoint Inhibitors $w P $a inhibítory imunitných kontrolných bodov
550		$7 sllk_us_auth*d060908 $Y CTLA-4 Antigen $w p $a antigén CTLA-4
665		$a 2018(2012) $2 eng
680	9-	$i An anti-CTLA-4 ANTIGEN monoclonal antibody initially indicated for the treatment of certain types of metastatic MELANOMA. Its mode of actions may include blocking of CTLA-4 mediated inhibition of CYTOTOXIC T LYMPHOCYTES, allowing for more efficient destruction of target tumor cells. $2 eng
750	-2	$a Ipilimumab $2 eng
980		$x M

Počet záznamov: 1